Baxter International Inc (NYSE:BAX) SVP Andrew Frye sold 3,332 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $88.00, for a total value of $293,216.00. Following the sale, the senior vice president now owns 16,391 shares of the company’s stock, valued at approximately $1,442,408. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NYSE:BAX traded up $0.51 during mid-day trading on Friday, reaching $78.51. The stock had a trading volume of 3,017,392 shares, compared to its average volume of 2,768,937. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72. The company has a market cap of $39.56 billion, a P/E ratio of 25.74, a price-to-earnings-growth ratio of 2.00 and a beta of 0.97. Baxter International Inc has a 1 year low of $61.40 and a 1 year high of $89.93. The business’s 50 day moving average price is $84.08 and its 200 day moving average price is $82.11.
Hedge funds have recently modified their holdings of the business. 1 North Wealth Services LLC purchased a new stake in Baxter International during the third quarter valued at approximately $27,000. Weaver Consulting Group purchased a new stake in shares of Baxter International in the first quarter worth approximately $25,000. Old North State Trust LLC purchased a new stake in shares of Baxter International in the third quarter worth approximately $31,000. Personal Wealth Partners purchased a new stake in shares of Baxter International in the second quarter worth approximately $29,000. Finally, TRUE Private Wealth Advisors purchased a new stake in shares of Baxter International in the second quarter worth approximately $29,000. Institutional investors and hedge funds own 83.45% of the company’s stock.
Several analysts have issued reports on BAX shares. Wells Fargo & Co set a $95.00 price target on Baxter International and gave the company a “buy” rating in a report on Friday, July 26th. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. UBS Group dropped their price objective on Baxter International from $98.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, October 28th. Royal Bank of Canada set a $87.00 price objective on Baxter International and gave the stock a “hold” rating in a research note on Friday, July 26th. Finally, Deutsche Bank initiated coverage on Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Baxter International presently has a consensus rating of “Buy” and a consensus target price of $90.14.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.